This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Mease, P. J. et al. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/keac353 (2022)
Coates, L. C. et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. https://doi.org/10.1002/art.42280 (2022)
Baraliakos, X. et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. https://doi.org/10.1002/art.42282 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Phillips, R. Bimekizumab safe and effective for AS and PsA in long-term trials. Nat Rev Rheumatol 18, 494 (2022). https://doi.org/10.1038/s41584-022-00823-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-022-00823-2